☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Eslicarbazepine launched

A new antiepileptic medication has been launched in the UK as adjunctive therapy for the treatment of partial-onset seizures, with or without secondary generalisation, in adults.

Eslicarbazepine acetate (Zebinix®) is available as 800mg tablets in packs of 30 at a cost of £154.20. The drug is an active metabolite of oxcarbazepine and has the same mechanism of action as carbamazepine.

Concomitant use with oxcarbazepine is not recommended due to the theoretical risk of overexposure to the active metabolites of these drugs. The only apparent advantage of this drug over oxcarbazepine is the once daily administration however this comes at a significant cost.

Action: Clinicians should be aware of this new drug. This new drug may be useful where compliance with twice daily oxcarbazepine is incomplete but changes to therapy should ideally be secondary care led.

Share 'Eslicarbazepine launched' by emailShare 'Eslicarbazepine launched' on FacebookShare 'Eslicarbazepine launched' on TwitterShare 'Eslicarbazepine launched' on LinkedInShare 'Eslicarbazepine launched' on reddit


No Comments to “Eslicarbazepine launched”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.